First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate can... von Bianchini, D, Omlin, A, Pezaro, C, Lorente, D, Ferraldeschi, R, Mukherji, D, Crespo, M, Figueiredo, I, Miranda, S, Riisnaes, R, Zivi, A, Buchbinder, A, Rathkopf, D E, Attard, G, Scher, H I, de Bono, J, Danila, D C

Volltext

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy von Beer, Tomasz M, Armstrong, Andrew J, Rathkopf, Dana E, Loriot, Yohann, Sternberg, Cora N, Higano, Celestia S, Iversen, Peter, Bhattacharya, Suman, Carles, Joan, Chowdhury, Simon, Davis, Ian D, de Bono, Johann S, Evans, Christopher P, Fizazi, Karim, Joshua, Anthony M, Kim, Choung-Soo, Kimura, Go, Mainwaring, Paul, Mansbach, Harry, Miller, Kurt, Noonberg, Sarah B, Perabo, Frank, Phung, De, Saad, Fred, Scher, Howard I, Taplin, Mary-Ellen, Venner, Peter M, Tombal, Bertrand

Volltext

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second int... von Chi, K.N., Sandhu, S., Smith, M.R., Attard, G., Saad, M., Olmos, D., Castro, E., Roubaud, G., Pereira de Santana Gomes, A.J., Small, E.J., Rathkopf, D.E., Gurney, H., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Urtishak, K., del Corral, A., Francis, P., Kim, W., Efstathiou, E.

Volltext

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel von Chi, K.N., Kheoh, T., Ryan, C.J., Molina, A., Bellmunt, J., Vogelzang, N.J., Rathkopf, D.E., Fizazi, K., Kantoff, P.W., Li, J., Azad, A.A., Eigl, B.J., Heng, D.Y.C., Joshua, A.M., de Bono, J.S., Scher, H.I.

Volltext

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide von Rathkopf, D.E., Smith, M.R., Ryan, C.J., Berry, W.R., Shore, N.D., Liu, G., Higano, C.S., Alumkal, J.J., Hauke, R., Tutrone, R.F., Saleh, M., Chow Maneval, E., Thomas, S., Ricci, D.S., Yu, M.K., de Boer, C.J., Trinh, A., Kheoh, T., Bandekar, R., Scher, H.I., Antonarakis, E.S.

Volltext

AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-r... von de Bono, J.S., Hansen, A., Choudhury, A.D., Cook, N., Heath, E.I., Higano, C., Linch, M., Martin-Liberal, J., Rathkopf, D.E., Wisinski, K.B., Barry, S., de Bruin, E., Brugger, W., Colebrook, S., Klinowska, T., Moschetta, M., Mortimer, P.G.S., Siu, L.L., Shapiro, G.

Volltext

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-r... von Rathkopf, D.E., Patel, M.R., Choudhury, A.D., Rasco, D., Lakhani, N., Hawley, J.E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K.D., Emamekhoo, H., Reichert, Z.R., Nguyen, M.H., Wells, A.L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., Arora, V.K., Pourdehnad, M., Armstrong, A.J.

Volltext

833PAZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castra... von de Bono, J S, Hansen, A, Choudhury, A D, Cook, N, Heath, E I, Higano, C, Linch, M, Martin-Liberal, J, Rathkopf, D E, Wisinski, K B, Barry, S, de Bruin, E, Brugger, W, Colebrook, S, Klinowska, T, Moschetta, M, Mortimer, P G S, Siu, L L, Shapiro, G

Volltext

A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL stu... von Bryce, A.H., Alumkal, J.J., Armstrong, A., Higano, C.S., Iversen, P., Sternberg, C.N., Rathkopf, D.E., Loriot, Y., de Bono, J., Tombal, B., Abhyankar, S., Lin, P., Krivoshik, A., Phung, D., Beer, T.M.

Volltext

Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus predniso... von Carles, J., Davis, I., de Bono, J.S., Fizazi, K., Gerritsen, W., Rathkopf, D.E., Ryan, C.J., Saad, F., Steuber, T., Wilding, G., Park, Y.C., Charnas, R., De Porre, P., Van Poppel, H.

Volltext

Risk of rash and stomatitis with temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis von Gomez Fernandez, C., Balagula, Y., Wu, S., Su, X., Feldman, D. R., Rathkopf, D. E., Lacouture, M. E.

Volltext

A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial von Antonarakis, E. S., Heath, E. I., Smith, D. C., Rathkopf, D. E., Blackford, A. L., Danila, D. C., King, S., Frost, A., Carducci, M. A.

Volltext

A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (... von Rathkopf, D. E., Danila, D. C., Slovin, S. F., Morris, M. J., Steinbrecher, J. E., Chen, Y., Fleisher, M., Larson, S. M., Sawyers, C. L., Scher, H. I.

Volltext

Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer... von Rathkopf, D. E., Danila, D. C., Morris, M. J., Slovin, S. F., Borwick, L. S., Momen, L., Curley, T., Arauz, G., Larson, S. M., Fleisher, M., Rosen, N., Scher, H. I.

Volltext

Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based... von Danila, D. C., Anand, A., Sung, C. C., Leversha, M., Rathkopf, D. E., Morris, M. J., Slovin, S. F., Molina, A., Fleisher, M., Scher, H. I.

Volltext

Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resist... von Rathkopf, D. E., Danila, D. C., Chudow, J. J., Morris, M. J., Slovin, S. F., Fine, S., Fox, J. J., Larson, S. M., Rosen, N., Scher, H. I.

Volltext

Phase I trial of pulse-dose vorinostat with flavopiridol in solid tumors von Dickson, M. A., Rathkopf, D. E., Grant, S., Roberts, J. D., Reid, J. M., Ames, M. M., McGovern, R. M., Gonen, M., Dials, H. J., Schwartz, G. K.

Volltext

Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone von Carrasquillo, J. A., O' Donoghue, J. A., Pandit-Taskar, N., Rathkopf, D. E., Aksnes, A., Viner, C. L., Hong, C. T., Larson, S. M., Scher, H. I., Morris, M. J.

Volltext

Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC) von Rathkopf, D. E., Chi, K. N., Vaishampayan, U., Hotte, S., Vogelzang, N., Alumkal, J., Agrawal, M., Nydam, T. M., Fandi, A., Scher, H. I.

Volltext